Jack W. Singer

机构：Endeavor Health, University of California, San Francisco, North Shore University Hospital · ORCID：0000-0003-4001-4549

发表论文 596 篇 · 总被引 35590 次 · h-index 100

代表论文

• Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis (2018 · JAMA Oncology · 被引 399)
• Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy (2018 · Oncotarget · 被引 157)
• Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation (2018 · Proceedings of the National Academy of Sciences · 被引 75)
• Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes (2018 · Leukemia · 被引 74)
• Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures (2019 · PLoS ONE · 被引 50)
• Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis (2018 · Journal of Experimental Pharmacology · 被引 27)